Giuseppe Pasqualetti1, Gennaro Pagano1, Giuseppe Rengo1, Nicola Ferrara1, Fabio Monzani1. 1. Geriatrics Unit (G.Pas., F.M.), Department of Clinical & Experimental Medicine, University of Pisa, Pisa, Italy; King's College London (G. Pag.), Department of Clinical Neuroscience, London, United Kingdom; Department of Translational Medical Sciences (G.Pag., G.R., N.F.), Federico II University of Naples, Naples, Italy; and Salvatore Maugeri Foundation (G.R., N.F.), IRCCS Institute of Telese Terme, Benevento, Italy.
Abstract
BACKGROUND: The association between subclinical hypothyroidism (sHT) and cognitive impairment or risk of dementia is not well-defined, especially in the elderly, where the assessment of central nervous system function is challenging. The aim of this systematic review and meta-analysis was to evaluate the possible effect of sHT on cognitive decline and the risk of dementia. METHODS: Cognitive function was the primary outcome, evaluated as composite endpoint of incidence or prevalence of dementia or difference of Mini Mental State Examination, Wechsler Adult Intelligence Scale, and Wechsler Memory Scale-Revised scores. RESULTS: Thirteen studies were included in the meta-analysis. A significant risk of cognitive alteration was observed only in sHT individuals younger than age 75 years: composite endpoint odds ratio (OR) 1.56 (95% confidence interval [CI] 1.07-2.27, P = .02, I(2) = 82.5%), risk of dementia OR 1.81 (95% CI 1.43-2.28, P < .01, I(2) = 35%). Mean serum thyroid-stimulating hormone (TSH) levels and the OR of composite endpoint were positively correlated. No significant effect of sHT was found when considering all the studies as a whole: composite endpoint OR 1.26 (95% CI 0.96-1.66, P = .09, I(2) = 87.2%), risk of dementia OR 1.42 (95% CI, 0.97-2.07, P = .07, I(2) = 66.8%), Mini Mental State Examination mean difference -0.059 (95% CI -0.464 to 0.346 P = .78, I(2) = 51.8%). CONCLUSIONS: This meta-analysis demonstrates a relationship between sHT and cognitive impairment only in individuals younger than 75 years of age and those with higher TSH concentrations. No correlation was found while considering all the studies as a whole. The lack of utilization of age-related serum TSH reference ranges and consequent potential misdiagnosis of sHT in older people may account for this.
BACKGROUND: The association between subclinical hypothyroidism (sHT) and cognitive impairment or risk of dementia is not well-defined, especially in the elderly, where the assessment of central nervous system function is challenging. The aim of this systematic review and meta-analysis was to evaluate the possible effect of sHT on cognitive decline and the risk of dementia. METHODS: Cognitive function was the primary outcome, evaluated as composite endpoint of incidence or prevalence of dementia or difference of Mini Mental State Examination, Wechsler Adult Intelligence Scale, and Wechsler Memory Scale-Revised scores. RESULTS: Thirteen studies were included in the meta-analysis. A significant risk of cognitive alteration was observed only in sHT individuals younger than age 75 years: composite endpoint odds ratio (OR) 1.56 (95% confidence interval [CI] 1.07-2.27, P = .02, I(2) = 82.5%), risk of dementia OR 1.81 (95% CI 1.43-2.28, P < .01, I(2) = 35%). Mean serum thyroid-stimulating hormone (TSH) levels and the OR of composite endpoint were positively correlated. No significant effect of sHT was found when considering all the studies as a whole: composite endpoint OR 1.26 (95% CI 0.96-1.66, P = .09, I(2) = 87.2%), risk of dementia OR 1.42 (95% CI, 0.97-2.07, P = .07, I(2) = 66.8%), Mini Mental State Examination mean difference -0.059 (95% CI -0.464 to 0.346 P = .78, I(2) = 51.8%). CONCLUSIONS: This meta-analysis demonstrates a relationship between sHT and cognitive impairment only in individuals younger than 75 years of age and those with higher TSH concentrations. No correlation was found while considering all the studies as a whole. The lack of utilization of age-related serum TSH reference ranges and consequent potential misdiagnosis of sHT in older people may account for this.
Authors: Meritxell Tost; José Antonio Monreal; Antonio Armario; Juan David Barbero; Jesús Cobo; Clemente García-Rizo; Miquel Bioque; Judith Usall; Elena Huerta-Ramos; Virginia Soria; Javier Labad Journal: Clin Drug Investig Date: 2020-01 Impact factor: 2.859
Authors: T Juárez-Cedillo; L Basurto-Acevedo; S Vega-García; A Sánchez-Rodríguez Martha; R Retana-Ugalde; E Juárez-Cedillo; C Gonzalez-Melendez Roberto; J Escobedo-de-la-Peña Journal: J Endocrinol Invest Date: 2017-03-25 Impact factor: 4.256
Authors: Mary H Samuels; Rajani Kaimal; Avantika Waring; Howard A Fink; Kristine Yaffe; Andrew R Hoffman; Eric Orwoll; Douglas Bauer Journal: Thyroid Date: 2016-09 Impact factor: 6.568
Authors: Carole E Aubert; Douglas C Bauer; Bruno R da Costa; Martin Feller; Carole Rieben; Eleanor M Simonsick; Kristine Yaffe; Nicolas Rodondi Journal: Clin Endocrinol (Oxf) Date: 2017-09-14 Impact factor: 3.478
Authors: Carole Rieben; Daniel Segna; Bruno R da Costa; Tinh-Hai Collet; Layal Chaker; Carole E Aubert; Christine Baumgartner; Osvaldo P Almeida; Eef Hogervorst; Stella Trompet; Kamal Masaki; Simon P Mooijaart; Jacobijn Gussekloo; Robin P Peeters; Douglas C Bauer; Drahomir Aujesky; Nicolas Rodondi Journal: J Clin Endocrinol Metab Date: 2016-09-30 Impact factor: 5.958